Faculty, Staff and Student Publications

Publication Date

1-8-2025

Journal

Blood Cancer Discovery

DOI

10.1158/2643-3230.BCD-24-0171

PMID

39565177

PMCID

PMC11707511

PubMedCentral® Posted Date

11-20-2024

PubMedCentral® Full Text Version

Post-print

Abstract

In recent years, there has been tremendous interest surrounding the integration of venetoclax into both non-intensive and intensive chemotherapy regimens for AML. However, with this increasing utilization of venetoclax, considerable questions surrounding key issues such as dosing strategies and the practicality of venetoclax administration have arisen. This review highlights the evolution of venetoclax-based regimens in AML and provides a commentary on notable practical considerations when utilizing this agent.

Keywords

Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Humans, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.